Huadong Medicine Co., Ltd. (SHE: 000963) announced clinical trial approval from China’s National Medical Products Administration (NMPA) for HDM2024, a Category 1 biologic drug and novel bispecific antibody-drug conjugate (Bs-ADC) targeting EGFR and HER3 for advanced solid tumor treatment. The approval follows earlier FDA clearance this month, enabling parallel China-U.S. development of the dual-receptor blocking ADC with DNA topoisomerase I inhibitor payload.
Regulatory Milestone
Item
Detail
Agency
NMPA (China) – FDA approved earlier March 2026
Approval Type
Clinical trial authorization (IND)
Product
HDM2024 – bispecific ADC (Bs-ADC)
Developer
Huadong Medicine Co., Ltd. (SHE: 000963)
Drug Class
Category 1 biologic (innovative)
Indication
Advanced solid tumors
Dual Approval
China + U.S. synchronized – global development strategy
Signal blockade + direct cytotoxicity – dual anti-tumor action
Strategic Context & Competitive Position
Factor
Implication
EGFR/HER3 Rationale
EGFR mutated/overexpressed in NSCLC, colorectal, head/neck; HER3 upregulated in EGFR-resistant tumors – dual targeting addresses acquired resistance and broader tumor spectrum
Bispecific ADC Differentiation
vs. patritumab deruxtecan (HER3-ADC, Daiichi) and cetuximab-based ADCs – HDM2024’s EGFR co-targeting may improve internalization efficiency and tumor selectivity
Topoisomerase I Payload Trend
DXd-derivative class (deruxtecan, etc.) established; HDM2024 uses similar mechanism with bispecific delivery advantage
Huadong Biotech Expansion
Category 1 biologic approval validates innovation pivot beyond traditional pharma distribution; ADC platform emerging as core capability
Global Development
China-U.S. parallel trials enable regulatory efficiency and ex-China partnership potential
Clinical Timeline: Phase I Q2 2026 initiation (China and U.S.); dose-escalation in EGFR/HER3-expressing solid tumors; preliminary efficacy 2027
Commercial Potential: Peak sales RMB 500 million–1 billion in China; global licensing opportunity $300+ million given differentiated bispecific approach
Forward‑Looking Statements This brief contains forward‑looking statements regarding Phase I enrollment, safety profile, and global partnership potential for HDM2024. Actual results may differ due to bispecific ADC manufacturing complexity, competitive dynamics with HER3-targeted therapies, and regulatory coordination between China and U.S. trials.-Fineline Info & Tech
By Fineline Cube